Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Alone or With CMP-001 in Operable Melanoma
NCT04708418Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of vidutolimod in melanoma, sponsored by National Cancer Institute. Started Oct 2021; status: active, not recruiting.
02
Drugs
vidutolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04708418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708418.